You are here

  • Home
  • Archive
  • Volume 81, Issue 8
  • Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’

Article Text

Article menu

Download PDFPDF

Correspondence
Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’
Free
  1. Attila Pethoe-Schramm1,
  2. Jenny Devenport2,
  3. William Reiss3
  1. 1 Product Development Medical Affairs, F Hoffmann-La Roche AG, Basel, Switzerland
  2. 2 Product Development Biostatistics, F Hoffmann-La Roche AG, Basel, Switzerland
  3. 3 United States Medical Affairs, Genentech, South San Francisco, California, USA
  1. Correspondence to Dr Jenny Devenport, F Hoffmann-La Roche AG, Basel 4053, Switzerland; jenny.devenport{at}roche.com

https://doi.org/10.1136/annrheumdis-2020-218365

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the article ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’ by Shafran et al.1 This was an exploratory analysis of multiple studies and concluded that baseline C-reactive protein (CRP) and its early course may inform, to some extent, the estimation of potential therapeutic success in patients with rheumatoid arthritis (RA) treated with tocilizumab. Although we appreciate the pursuit of personalised treatment decisions in RA, this conclusion is not the only interpretation, and previously published analyses of these data further characterise the relationship between CRP and clinical outcomes with tocilizumab treatment in patients with RA.2

    Shafran et al 1 concluded that baseline and early changes in CRP levels are predictive of tocilizumab response. Although CRP levels were affected differently by tocilizumab than rituximab or methotrexate treatment, decreasing to near zero in tocilizumab-treated patients, …

    View Full Text

    Linked Articles